Mutations in LRRK2 (leucine-rich repeat kinase 2) are associated with both familial and sporadic PD (Parkinson's disease). LRRK1 (leucine-rich repeat kinase 1) shares a similar domain structure with LRRK2, but it is not linked to PD. LRRK proteins belong to a gene family known as ROCO, which codes for large proteins with several domains. All ROCO proteins have a ROC (Ras of complex proteins) GTPase domain followed by a domain of unknown function [COR (C-terminal of ROC)]. LRRK2, LRRK1 and other ROCO proteins also possess a kinase domain. To date, the function of LRRK1 and both the physiological and the pathological roles of LRRK2 are only beginning to unfold. The comparative analysis of these two proteins is a strategy to single out the specific properties of LRRKs to understand their cellular physiology. This comparison is the starting point to unravel the pathways that may lead to PD and eventually to develop therapeutic strategies for its treatment. In the present review, we discuss recently published results on LRRK2 and its paralogue LRRK1 concerning their evolutionary significance, biochemical properties and potential functional roles.
Introduction
PD (Parkinson's disease) is a neurodegenerative disorder with no cure. Mutations in LRRK2 (leucine-rich repeat kinase 2) are the most common genetic causes of both familial late-onset parkinsonism and apparently sporadic PD [1, 2] . To date, five amino acid substitutions in LRRK2 have been identified as pathogenic (R1441G/C, Y1699C, G2019S and I2020T) [3] . In certain populations, the LRRK2 G2019S mutation is found in up to 40 % of PD patients [4] . The LRRK2 gene encodes a large multidomain protein characterized by the presence of leucine-rich repeats and two enzymatic units: a GTPase domain similar to Ras small GTPases and a kinase domain, belonging to the TKL (tyrosine kinase-like) kinases, which shows high similarity to MLKs (mixed-lineage kinases) [5] [6] [7] . In vertebrates, the LRRK2 gene has one paralogue: LRRK1 (leucine-rich repeat kinase 1). The two proteins display a conserved domain architecture [8, 9] and are both members of the ROCO family [10] . Moreover, both proteins are expressed in the brain [8, 11, 12] and are basally phosphorylated [11] . However, despite their close homology and their similar expression profile, no mutations in LRRK1 have been genetically associated with PD [8] . Interestingly, it was shown that mutations in LRRK1 mimicking LRRK2 pathological mutations are less toxic than pathogenic mutations in LRRK2
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in vitro [11] . In the present paper, we review the available structural, biochemical and functional data on LRRK1 and LRRK2, and attempt to link them to specific biological pathways.
Evolutionary and structural considerations
Discovered in the 1990s [13, 14] , ROCO proteins were formally described and named by Bosgraaf and Van Haastert in 2003 [10] . This group of proteins contains two conserved domains named ROC (Ras of complex proteins), a GTPase domain with high sequence similarity to Ras and other related small GTPases, and COR (C-terminal of ROC), a domain of unknown function, but a fingerprint of all ROCO proteins. The presence of this characteristic ROC-COR domain made it possible to trace its evolution and the functional correlation among the members of this family [15] .
Bioinformatics studies revealed that ROCO genes are present both in prokaryotes and eukaryotes [10] . The first ROCO protein was discovered in the slime mould Dictyostelium discoideum where 11 ROCO genes were found. Mammals contain four ROCO genes: LRRK1, LRRK2, DAPK1 (death-associated kinase 1) and MFHAS1 (malignant fibrous histiocytoma amplified sequence 1). In animals, the evolution of LRRK proteins is particularly interesting. On the basis of bioinformatics analysis of the LRRK ROC and COR domains, Marin [7] proposed a phylogenetic reconstruction tracking the origin of the LRRK genes. He suggests that two independent events of gene duplication from an ancestral protogene termed 'proto-LRRK' led to three LRRK genes. In cnidarians, an additional gene duplication event yielded a fourth LRRK gene. Conversely, protostomes such as Drosophila melanogaster or Caenorhabditis elegans have lost LRRK1 and LRRK2 and maintained 'LRRK3' (pLRRK3), whereas deuterostomes, and vertebrates in particular, have lost 'LRRK3', but maintained LRRK1 and LRRK2 (dLRRK1 and dLRRK2) [7, 16] . This is particularly interesting in that Drosophila and, in part, Caenorhabditis have been largely used to investigate LRRK2 pathophysiology [17] . Given that pLRRK3 appears to be evolutionarily different from dLRRK2, this suggests that caution should be taken when translating dLrrk (Drosophila LRRK) function to human LRRK2 function. Of note, published studies show that overexpression of dLrrk or LRRK2 mutants on fruitfly models, as well as dLrrk depletion, causes selective degeneration of dopaminergic neurons and motor function deficits [18] [19] [20] . It was also demonstrated that both dLrrk and LRRK2 can phosphorylate the 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) [19] . These results suggest that these two proteins are likely to possess a conserved function.
LRRK1 and LRRK2 share a similar domain organization (Figure 1) , which includes the presence of leucine-rich and ankyrin-like repeats at the N-terminus and a ROC-COR domain followed by a serine/threonine kinase domain (ROC-COR-kinase module). Among mammalian ROCO proteins, the kinase domain of DAPK1 is phylogenetically distinct from those of LRRK1 and LRRK2. In particular, the DAPK1 kinase domain can be ascribed to the CaMK (Ca 2 + /calmodulin-dependent kinase) group, whereas MF-HAS1 does not contain a kinase domain. In contrast, LRRK1 and LRRK2 kinase domains belong to the TKL group of human protein kinases [6] , whose members show sequence similarity to both serine/threonine and tyrosine kinases. Within the TKL group, the LRRK kinase domains most resemble MLKs and RIPKs (receptor-interacting protein kinases), which are crucial sensors of cellular stress [6, 7, 21] . The major differences between LRRK1 and LRRK2 are at the N-terminal region, where LRRK2 contains a large number of unique repeats [7, 15, 16] . Interestingly, the kinase activity of LRRK2 is inhibited by the N-terminal region, as truncated forms of LRRK2, lacking the first 1326 amino acids, display a dramatic increase in kinase activity [22, 23] . Moreover, phosphorylated serine residues at positions 910 and 935 of LRRK2 have been shown to bind 14-3-3 proteins; this binding controls LRRK2 intracellular localization and probably also its cellular function [24] [25] [26] . Furthermore, in silico analysis indicates that the C-terminal region of LRRK2 shares a high degree of similarity with WD40 repeats known to form a circularized β-propeller structure. At the C-terminus, LRRK1 and LRRK2 are highly divergent, and LRRK1 does not display significant similarity with WD40 structures [27] . Interestingly, the C-terminal region in LRRK2 is indispensable for kinase activity, and even deletion of a few amino acids at the C-terminus results in complete abolishment of kinase function [22] . Overall, the absence of a complex and extended N-terminal region from LRRK1, the minimal similarity of the C-terminal tail and the lack of homologous residues for 14-3-3 binding may represent important differences that affect protein function. Despite the major differences observed at the two terminal regions, pathological mutations in LRRK2 segregating with PD are clustered within the more conserved ROC-CORkinase tri-domain. This observation suggests a key role for the tri-domain in governing LRRK proteins' divergent functions, which are likely to depend on the diverse domains recruited in evolution, up to the possible implication of LRRK2 in pathological effects.
Biochemical features
As described above, despite clear differences at the Nand C-termini, the ROC-COR-kinase domain architecture is clearly preserved in both proteins. To date, the precise relationship between GTP binding and kinase activity of LRRK2 is unclear, as well as how mutations affect these activities and change protein function. Thus biochemical data obtained for LRRK1 may help to elucidate the molecular mechanism leading to LRRK2-dependent PD.
LRRK2 is a serine/threonine kinase that undergoes autophosphorylation in vitro [23, [28] [29] [30] . Pathological mutations in the ROC-COR domain (R1441G/C and Y1699C) decrease GTPase activity, whereas there are clear indications that the G2019S mutation in the kinase domain augments kinase activity [30, 31] . Because different mutations in different enzymatic domains cause the same pathological outcome, it is possible that an intramolecular regulatory interplay between the kinase and GTPase domains may exist. Since LRRK2 was classified as a G-protein, which cycles between GDP-and GTP-bound conformations [32] , it was hypothesized that, upon GDP binding to the active site in ROC, kinase activity is decreased, whereas, upon GTP binding, kinase activity is increased [33] . This model is supported by evidence that the ROC domain stimulates kinase activity [34, 35] and therefore alteration of GTPase activity may result in deregulated kinase activity. On the other hand, the effect of binding of non-hydrolysable GTP analogues on kinase activity is modest, and binding of GDP has no measurable effect on kinase activity [35, 36] . An alternative model predicts that the LRRK2 kinase domain regulates GTPase activity through autophosphorylation and that the GTPase activity itself is the signalling output. Supporting this model, several studies have found that potential autophosphorylation sites are mainly clustered within the ROC domain [23, [37] [38] [39] [40] [41] . In analogy to RTKs (receptor tyrosine kinases) that undergo dimerization and subsequent autophosphorylation at multiple sites upon binding of the extracellular messenger [42] , LRRKs may also dimerize after recruiting an interacting partner and undergo autophoshorylation that then regulates its GTPase activity. Several lines of evidence indicate that LRRK2 is predominantly a dimer in cells [23, [43] [44] [45] .
At present, little is known about LRRK1 biochemical properties, and only a few reports describing either GTPase or kinase activities have been published. Korr et al. [9] proposed that LRRK1 acts as GDP/GTP-binding protein via its ROC domain [9] and undergoes autophosphorylation, although with lower efficiency than LRRK2 [9, 11, 46] . The kinase activity of LRRK1 is abolished by artificial mutations predicted to interfere with kinase activity, and the kinase enzymatic regulation seems to be affected by the fraction of saturation of the GTP-binding site, supporting the idea that the GTPase domain influences kinase activity [9] .
One general difficulty in studying the function of LRRKs is that there are no clearly identified physiological substrates for LRRK2 kinase activity and no verified functional outputs for GTPase activity. In addition, none of the commonly used generic kinase substrates, such as histone H1, casein or MBP (myelin basic protein) are phosphorylated by LRRK1 [9] . Furthermore, biochemical studies designed to unravel the molecular mechanisms that govern LRRK protein function are hindered by the lack of an efficient purification protocol of the full-length recombinant LRRK1 and LRRK2 proteins. To date, published studies that investigate the biochemical properties of the proteins report data on either the truncated recombinant LRRK2 [47, 48] or recombinant protein with large affinity tags [22] designed to simplify the purification procedures. Furthermore, full-length LRRK2 expression is not feasible in prokaryotes, and the use of heterologous sources (insect or mammalian cells) yield only a few micrograms of recombinant material, a quantity still insufficient to either embark on structural studies or to set up crystallographic trials to define the three-dimensional structure, to date limited to the individual ROC domain [43] .
Role of human LRRKs: intersecting or independent functions?
As mentioned above, mutations in the LRRK2 gene account for a significant proportion of autosomal-dominant and apparently sporadic PD, respectively 10 % and 1-2 % of all PD cases, whereas PD-linked mutations in LRRK1 have not been reported [8] . Although both LRRKs are basally phosphorylated, bind guanine nucleotides and display partial intracellular co-localization [9, 11] , the introduction of disease-associated LRRK2 mutations into LRRK1 does not affect the autophosphorylation activity of LRRK1, as well as the propensity of LRRK1 to induce cell death, as observed for mutated LRRK2 proteins [9, 11] . As mentioned above, LRRK2 is predominantly present in the cell as a complex compatible with the size of a dimer [23, [43] [44] [45] , and its dimeric nature seems to be responsible for the modulation of kinase activity [44] . In addition, LRRK2 was observed to exist also as a monomer, probably inactive [44, 45, 49] . Given the high degree of homology and the similar domain organization between LRRK1 and LRRK2, it is plausible to assume that LRRK1 has analogous quaternarystructural properties. This is supported by a study showing that dimerization is a general feature among members of the ROCO protein kinase family (LRRK2, LRRK1 and DAPK1) [50] . One report also suggests heterodimerization between LRRK1 and LRRK2 [51] . Similarly, G-proteins activated by nucleotide-dependent dimerization (GADs), a class of proteins to which LRRKs have been ascribed, undergo pseudo-trans-homodimerization, a reaction that can occur between two different G-proteins of the same family with identical active-site residues [32] . In this scenario, LRRK1-LRRK2 heterodimerization could influence the dimer-oligomer equilibrium of LRRK2 and affect its kinase activity. However, a role for LRRK1 as modulator of LRRK2 quaternary structure needs to be explored further, in particular, investigating whether LRRK2 pathological mutations could disrupt heterodimerization.
Although in the last few years large efforts have been made to elucidate the physiological and pathological function of LRRK2, the LRRK2 signalling pathways remain elusive. LRRK2 has been suggested to play a role in the control and maintenance of neurite length [52] [53] [54] , in activation of apoptosis through interaction with the death adaptor FADD (Fas-associated death domain) [55] , in controlling protein translation through phosphorylation of 4E-BP1 [19] , and interaction with the microRNA pathway to regulate protein synthesis [56] . Several groups have also reported that LRRK2 interacts with tubulins and the actin cytoskeleton, suggesting a role in cytoskeleton dynamics [57] [58] [59] [60] . More recently, several papers proposed a role for LRRK2 in controlling the autophagic process [61] [62] [63] [64] [65] , suggesting that impairment in autophagic flux as a consequence of pathological mutations may deregulate proteins and organelle homoeostasis and, in turn, lead to neurodegeneration. The cellular function of LRRK1 has been much less scrutinized because LRRK1 is not clearly linked to a human disease. In 2011, Hanafusa et al. [66] published an elegant paper demonstrating that LRRK1 plays a role in endocytosis of EGFR (epidermal growth factor receptor). In this study, it was shown that LRRK1 forms a complex with activated EGFR through an interaction with Grb2 (growth-factor-receptor-bound The expression levels of LRRK1 and LRRK2 are quite similar in several organs such as the heart (3), the lungs (2) and muscles (4). LRRK2 is highly expressed in the brain (1), the kidneys (7) and in immune cells (9) , whereas LRRK1 is nearly absent from these sites. This difference between the two profiles is particular relevant as PD is a disease of the central nervous system and the phenotype observed in Lrrk2 − / − mice shows accumulation of α-synuclein in the kidneys. 1, brain; 2, lungs; 3, heart; 4, muscles; 5, stomach; 6, liver; 7, kidneys; 8, gut; 9, immune system. Upper inset reprinted from Neuron, 44(4), Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., Stoessl, A.J., Pfeiffer, R.F., Patenge, N., Carbajal, I.C., Vieregge, P., Asmus, F. protein 2). In addition, LRRK1 regulates EGFR transport from early to late endosomes. Recently, the same authors investigated further the mechanism by which LRRK1 regulates endosome trafficking [67] . They showed that EGFR regulates the kinase activity of LRRK1 via Tyr 944 phosphorylation. Mutation of LRRK1 at Tyr 944 (Y944F) abolishes EGF (epidermal growth factor)-stimulated tyrosine phosphorylation, resulting in hyperactivation of LRRK1 kinase activity and enhanced motility of EGF-containing endosomes towards the perinuclear region. Of note, Hanafusa et al. [66] did not observe an interaction of LRRK2 with the EGFR-Grb2 complex. However, LRRK2 was found to interact with AP-2 (adaptor protein 2) [60] , a protein that forms complexes involved in the internalization of activated EGFR [68] .
At the subcellular level, LRRK2 was shown to be diffusely distributed in the cytoplasm [11] , but also to associate with membranous and vesicular structures [45, 64, [69] [70] [71] . According to its partial membrane localization, there is evidence suggesting a role for LRRK2 in vesicle trafficking through interaction with presynaptic endocytic machinery [60, 71] and vesicle sorting between axons and dendrites [72] , as well as lysosomal function [61, 64] . In particular, LRRK2 interacts with early endosomal Rab5 [71] , and LRRK2 silencing in cultured neurons impairs synaptic exocytosis causing abnormal trafficking and distribution of presynaptic vesicles [60, 71] . As mentioned above, LRRK2 was shown to interact with α-and β-tubulins [57] [58] [59] , the microtubule components, suggesting that LRRK2 may control synaptic vesicle movement along axons. Of note, LRRK1 was found to interact with NudC and CLIP-170 (cytoplasmic linker protein 170) [66] , proteins involved in the dynein-mediated endocytosis process [73, 74] . Taken together, these observations imply that LRRK1 and LRRK2 may share convergent functions, possibly acting as scaffolds in different steps of the endocytic pathway.
Several studies also analysed LRRK mRNA and protein levels in different tissues and organs; these data indicate that the expression of the two proteins generally overlaps and, in some tissues, levels are comparable [11, 12, 51] . However, in organs such as the brain and the kidneys, LRRK2 mRNA expression is higher than that of LRRK1 [12] (Figure 2 ). This observation is particularly relevant since PD is a disease of the central nervous system, but also considering that a major phenotypic alteration reported from Lrrk2 − / − mice is observed in kidneys [65] . Specifically, Lrrk2 − / − mice show a striking accumulation and aggregation of α-synuclein in boxy cells of renal tubules in the cortical area of kidneys [65] . If LRRK1 and LRRK2 possess partially overlapping functions, then LRRK1 may compensate for the effects of LRRK2 deficiency only in those tissues where their expression is similar, but not in the brain or kidneys where LRRK1 expression is low.
To summarize, even if LRRK1 and LRRK2 originate from a common ancestor, it seems that they have become specialized for different functions. LRRK proteins possess a number of repeats with a low degree of conservation; these domains are known to be implicated in proteinprotein interactions [75] . LRRK proteins may exhibit a similar molecular mechanism with regard to ROC-CORkinase domain function, but interactions with different partners differentially regulate and target their cellular functions. Recent results strongly suggest that LRRK2 plays a role in inflammatory response [76] [77] [78] [79] [80] . Accordingly, its expression in immune cells and tissues was shown to be very high in comparison with other tissues, suggesting that hPBMCs (human peripheral blood mononuclear cells) and macrophages are good models to study LRRK2 function. One study shows that LRRK1 mRNA expression is present at very low levels in, or totally absent from, hPBMCs and, unlike LRRK2, LRRK1 protein expression is not induced by interferon γ [79] , suggesting that LRRK1 is not implicated in immune response functions. Since there is evidence that chronically activated microglia and astrocytes contribute to PD [81] , lack of LRRK1 in immune tissues may not compensate for LRRK2 function, thus leading to the pathological results observed in PD.
In conclusion, in order to shed more light on LRRK function and dysfunction, the next key steps will be to study in parallel the effects of double LRRK1 and LRRK2 deficiency in murine models, as well as the detailed signalling pathways regulated by the two proteins.
